Pro-FEIBA Study Quality-of-Life results

To determine the impact of prophylaxis with FEIBA (Factor VIII Inhibitor Bypassing Activity), health-related quality of life (HRQoL) was assessed using the Short-Form (SF)-36 Health Survey and the EQ-5D questionnaire in subjects aged ≥ 14 years. 18 of 19 patients completed the SF-36 survey and 16/19 completed the EQ-5D questionnaire before and after the on-demand therapy and prophylaxis periods.1

Subjects considered good responders (≥ 50% reduction in bleeding frequency) trended toward improved HRQoL while receiving FEIBA prophylaxis when compared to on-demand treatment, with some domains reaching statistical significance.1

  • A general trend toward improved HRQoL after prophylaxis was observed for the 18 evaluable patients in all SF-36 dimensions except for vitality/energy and physical functioning.1
  • After prophylaxis, good responders (n = 12) exhibited statistically and clinically significant differences in the SF-36 physical component score (P = 0.021), role-physical (P = 0.042), bodily pain (P = 0.015), and social functioning (P = 0.036).1
  • In all evaluable subjects, EQ-5D health profile demonstrated a trend toward improvement after prophylaxis (n = 16)(ns).1
    • Improvements did not differ from those observed after on-demand treatment among patients identified as good responders (n = 11).1
  • During prophylaxis, patients missed a significantly fewer mean number of days (4.2 vs. 19.3) from school or work because of bleeding than during on-demand treatment (P = 0.01).1
Learn about the PROOF Study >>

Notation

ns=not significant

References

  1. 1. Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia. 2013;19:736-743.

The results are in

In the Pro-FEIBA study (n=26), FEIBA prophylaxis showed a significant reduction in the frequency of bleeding events in severe haemophilia A patients with FVIII inhibitors Read more

Publications

Visit Haemophilia to read the PROOF Study and access to more articles related to managing haemophilia patients with inhibitors. Read more

Sustained activity

FEIBA offers a long dosing interval. Read more

Demonstrated efficacy in prophylaxis

Learn how FEIBA prophylaxis can reduce bleed frequency and preserve joints. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more